Fosamax (Alendronate) for Osteoporosis: Patient Guide

Fosamax (alendronate) is a bisphosphonate medication taken as a weekly oral pill to treat and prevent osteoporosis. It works by binding to bone mineral and inhibiting osteoclasts — the cells that break down bone — reducing bone resorption and gradually increasing bone density. It is one of the most extensively studied osteoporosis medications with over 30 years of clinical data.

Fosamax must be taken correctly or it won't work and can cause esophageal irritation: take it first thing in the morning on an empty stomach, with a full 8-oz glass of plain water only (no coffee, juice, or other beverages). Remain upright (standing or sitting) for at least 30 minutes after taking it, and don't eat or drink anything else during that time. Taking it incorrectly dramatically reduces absorption and increases the risk of esophageal side effects.

The most common side effects are upper GI symptoms: heartburn, difficulty swallowing, esophageal irritation, and stomach pain — particularly if taken incorrectly (lying down, not with enough water). Rare but more serious risks include osteonecrosis of the jaw (ONJ), which is primarily associated with IV bisphosphonates at high doses for cancer; and atypical femur fractures, which are rare stress fractures after very long-term use. Both risks are extremely low with the doses and durations used for osteoporosis.

Most guidelines recommend reassessing after 5 years of oral bisphosphonate therapy. Lower-risk patients may take a 'drug holiday' — stopping for 1–3 years while bone protection persists (bisphosphonates stay in bone for years after stopping). Higher-risk patients (prior hip or vertebral fracture) should typically continue beyond 5 years. Your endocrinologist will guide this decision based on your DEXA scans and fracture risk.

Yes — generic alendronate sodium is bioequivalent to brand-name Fosamax and is significantly less expensive. Most insurance plans cover generic alendronate. Binosto is a brand-name effervescent tablet version of alendronate that dissolves in water, which may be easier to tolerate for patients with swallowing difficulties.

Osteonecrosis of the jaw (ONJ) — exposed bone in the jaw that doesn't heal — is a rare but documented risk of bisphosphonate therapy. The risk with oral alendronate at osteoporosis doses is extremely low (estimated 1 in 10,000 to 1 in 100,000 patients). Risk is much higher with IV bisphosphonates at cancer doses. Good dental hygiene and notifying your dentist about bisphosphonate use are important precautions.